XML 15 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents $ 8,464,635 $ 4,939,955
Investments, held to maturity (net) 6,689,643
Accounts receivable 131,842
Prepaid expenses and other current assets 528,964 869,158
Total Current Assets 9,125,441 12,498,756
Property and Equipment, net 392,895 445,733
Other Assets    
Restricted cash 101,166 101,151
Deposits 69,798 69,798
Related party receivable 103,017 58,017
Deferred financing costs 21,600
Total Other Assets 273,981 250,566
Total Assets 9,792,317 13,195,055
Current Liabilities    
Accounts payable 501,225 1,980,676
Accrued expenses and other liabilities 830,173 1,846,907
Current portion of long term debt 2,040,979 3,133,958
Total Current Liabilities 3,372,377 6,961,541
Long Term Liabilities    
Long term debt, net of discount and current portion 839,560 3,589,036
Other long term liabilities 439,248 149,748
Total Liabilities 4,651,185 10,700,325
Commitments and Contingencies
Stockholders' Equity    
Common stock, $0.0002 par value; 50,000,000 shares authorized, 22,202,465 and 8,424,641 shares issued and outstanding at September 30, 2016 (unaudited) and December 31, 2015, respectively 4,124 1,366
Additional paid-in capital 60,704,297 48,566,451
Accumulated deficit (53,532,473) (44,430,703)
Accumulated other comprehensive loss (149,545) (86,584)
Total Stockholders' Equity- Heat Biologics, Inc. 7,026,403 4,050,530
Non-Controlling Interest (1,885,271) (1,555,800)
Total Stockholders' Equity 5,141,132 2,494,730
Total Liabilities and Stockholders' Equity $ 9,792,317 $ 13,195,055